天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> British Journal of Diabetes >>article

British Journal of Diabetes

IF: 0.4
Download PDF

Early impact of liraglutide in routine clinical use (ABCD nationwide liraglutide audit) on cardiovascular risk (UKPDS risk engine)

Published:5 June 2020 DOI: 10.15277/bjd.2020.243
Chris Walton,?S. Kassim,?R. Harper,?P. Mcdonald,?Ursula Brennan,?Janet Harding,?T. Htay,?R. Nayar,?A. Pernet,?S. Rowles,?K. Adamson,?K. Thong,?R. Ryder,?On?behalf?of Abcd Nationwide liraglutide audit contributors

Abstract

Aims: Liraglutide has been shown to reduce cardiovascular mortality in a cardiovascular safety study, but it is not known to what extent these results will be replicated in real practice with people with diabetes treated with liraglutide in the UK. We wished to explore the likely cardiovascular benefits by modelling 10-year reduction in cardiovascular events and mortality using data from the ABCD liraglutide audit database.Methods: The UKPDS risk engine 2.0 was applied to data collected in the ABCD liraglutide audit database before and at the earliest return to clinic between 3 and 9 months after commencing liraglutide, using the 747 of 6,959 records where all factors used by the risk engine were completely recorded.Results: There were significant falls in all factors used in the UKPDS cardiovascular disease (CVD) risk assessment other than HDL cholesterol which was unchanged. The UKPDS risk engine mean±SD 10-year coronary heart disease (CHD) risk fell by 2.7±7.6% from 18.7±13.0% to 16.1±11.6% (p<0.001). The 10-year fatal CHD risk fell by 2.3±6.5% from 13.7±11.1% to 11.4±9.8% (p<0.001). The 10-year stroke risk fell by 0.3±2.8% from 7.9±8.7% to 7.6±8.3% (p=0.003). The 10-year fatal stroke risk fell by 0.1±0.7% from 1.2±1.4% to 1.1±1.3% (p=0.001).Conclusion: Starting liraglutide reduced 10-year CVD risk. These data suggest that liraglutide used in routine clinical care in 100 patients could prevent three events of CHD or stroke and save two or more lives over the next 10 years.

Substances (1)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Liraglutide 204656-20-2 C172H265N43O51 467 suppliers $70.00-$1991.25

Similar articles

IF:8.3

Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study.

ACS Applied Materials & Interfaces Chia-Hsuin Chang, Yi-Cheng Chang,etc Published: 1 March 2015
IF:1

Liraglutide Overdose-Induced Acute Pancreatitis

Cureus Aljawhara R. Alsaadoun,?Tariq R AlSaadoun,etc Published: 1 January 2022